LTRN
Lantern Pharma Inc. (LTRN) ESG Analysis Analysis (2026)
Environmental
LTRN shows limited disclosed environmental intensity data, which reduces transparency versus peers that report emissions, energy, and waste metrics more comprehensively.
Zero reported R&D intensity may indicate a lighter innovation footprint, but it also limits evidence of environmental product or process improvements relative to peers.
The absence of disclosed gross profit and FCF margin data constrains assessment of capital available for environmental compliance and transition spending versus better-disclosing peers.
No material environmental controversies were provided, so the main relative weakness is disclosure depth rather than a clearly adverse operating environmental profile.
Social
LTRN provides no disclosed workforce, safety, or human-capital metrics here, which leaves its social positioning less visible than peers with fuller reporting.
Zero stock-based compensation to revenue suggests lower equity-based pay dilution, but it does not by itself demonstrate stronger employee alignment or retention practices versus peers.
The lack of reported R&D intensity limits evidence of talent investment and product stewardship, which are increasingly material social indicators in peer comparisons.
No controversy data was provided, so the score reflects incomplete social disclosure more than a confirmed disadvantage in labor or customer practices.
Governance
LTRN's negative debt-to-equity ratio and modest net debt-to-EBITDA suggest a relatively conservative balance-sheet structure, which can support governance resilience versus leveraged peers.
Zero stock-based compensation to revenue indicates restrained equity dilution, which is generally favorable for capital-allocation discipline relative to peers with heavier SBC usage.
However, the provided data do not include board independence, audit quality, or shareholder-rights metrics, leaving governance assessment less complete than for better-disclosed peers.
Overall governance appears acceptable rather than leading, because the available indicators are supportive but insufficient to establish a clear peer advantage across core oversight dimensions.
Overall Score
LTRN appears moderately positioned versus peers overall, with its main relative strength in conservative capital structure offset by limited ESG disclosure depth.
Score Driver: Limited Disclosure Across Material ESG Metrics Is The Decisive Factor Constraining Relative Positioning Versus Peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Lantern Pharma Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

